Article
Immunity to SARS-CoV-2 in a Dialyzed Patient Who Developed COVID-19 Twenty Days After the Second Dose of BNT162b2 Vaccine: a Case Report
2021-07-21
Abstract excerpt
<title>Abstract</title> <p>IntroductionEnd stage kidney disease (ESKD) and cancer have been identified as risk factors for severe and fatal cases of COVID-19, making vaccination in these patients a priority. Patients suffering from ESKD have a significantly weaker response to common vaccines than general population. However, humoral and cellular immune responses after two doses of RNA-based vaccine BNT162b2 (Pfiz...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- ebfe2cab-c5af-5cb1-ad6c-3528a1546723
- DOI
- 10.21203/rs.3.rs-711429/v1
